This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
EMEA Expansion to Support BSX Stock Amid Fierce Competition
by Zacks Equity Research
Boston Scientific successfully continues with its expansion of operations across different geographies outside the United States.
Should You Add Penumbra Stock to Your Portfolio Right Now?
by Zacks Equity Research
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Phibro Animal Health (PAHC) Is Up 8.62% in One Week: What You Should Know
by Zacks Equity Research
Does Phibro Animal Health (PAHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Phibro Animal Health Corporation (PAHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Phibro (PAHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Globus Medical Inks $250M Deal to Acquire Nevro: Stock to Gain?
by Zacks Equity Research
GMED is set to acquire all shares of Nevro in an all-cash transaction, unlocking new growth opportunities.
Is Phibro (PAHC) a Solid Growth Stock? 3 Reasons to Think "Yes"
by Zacks Equity Research
Phibro (PAHC) is well positioned to outperform the market, as it exhibits above-average growth in financials.
PAHC vs. GEHC: Which Stock Is the Better Value Option?
by Zacks Equity Research
PAHC vs. GEHC: Which Stock Is the Better Value Option?
Are Investors Undervaluing Phibro Animal Health (PAHC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Phibro (PAHC) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Review Phibro's (PAHC) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase
by Zacks Equity Research
Phibro's second-quarter fiscal 2025 results reflect the strong performance of the legacy Animal Health business.
Compared to Estimates, Phibro (PAHC) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Phibro (PAHC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Phibro Animal Health (PAHC) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Phibro (PAHC) delivered earnings and revenue surprises of 28.57% and 3.55%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Phibro Animal Health (PAHC) is a Strong Momentum Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Should Investors Hold Chemed Stock in Their Portfolio Now?
by Zacks Equity Research
CHE stays on investors' radar due to its robust prospects in the VITAS business and the resilient Roto-Rooter arm.
All You Need to Know About Phibro (PAHC) Rating Upgrade to Strong Buy
by Zacks Equity Research
Phibro (PAHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Is Omnicell Stock a Solid Pick for Your Portfolio Right Now?
by Zacks Equity Research
OMCL stays on investors' radar due to the strong performance of the Advanced Services portfolio.
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
by Zacks Equity Research
QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.
Phibro Animal Health (PAHC) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Phibro (PAHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why Phibro Animal Health (PAHC) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
BioLife Solutions, Inc. (BLFS) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Phibro (PAHC) is an Incredible Growth Stock: 3 Reasons Why
by Zacks Equity Research
Phibro (PAHC) possesses solid growth attributes, which could help it handily outperform the market.
PAHC vs. SYK: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
PAHC vs. SYK: Which Stock Is the Better Value Option?
CALID Arm Growth to Support Bruker Shares Amid Macro Issues
by Zacks Equity Research
BRKR's NANO Life Science fluorescence microscopy is gaining from product innovation and research demand.
Is Phibro Animal Health (PAHC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Thermo Fisher Stock Worth Holding on to in Your Portfolio?
by Zacks Equity Research
TMO continues to capture investors' attention due to its innovative product launches and trusted partnership status.